Kallikrein

Base Information

• Chemical Name: Kallikrein
• CAS No.: 9001-01-8
• Molecular Formula: N/A
• Molecular Weight: 0
• Mol file: 9001-01-8.mol

Synonyms:Arginineesteropeptidase;Bradykininogenase;Callicrein;Circuletin;Depot-Glumorin;Depot-Padutin;Dilminal D;E.C. 3.4.21.8;E.C. 3.4.4.21;Follipsin;Glumorin;Kalirechin;Kallidinogenase;Kallikrein esterase;Kininogenase;Kininogenin;Onokrein P;Padreatin;Padukrein;Padutin;Pancreatic kallikrein;Prokrein;Promotin;Urinary kallikrein;Urokallikrein;Yikai;SK 827;Substance R (enzyme);

Chemical Property of Kallikrein

Chemical Property:

• Appearance/Colour: White or off-white powder
• PSA: 0.00000
• LogP: 0.00000
• Storage Temp.: 2-8°C

Purity/Quality:

99% ^*data from raw suppliers

Safty Information:

• Pictogram(s): B
• Hazard Codes: B

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Biological functions: KLKB1 selectively cleaves Arg/Xaa and Lys/Xaa bonds, including Lys/Arg and Arg/Ser bonds in human KNG, to release BK. It also digests plasminogen to plasmin, and participates in the surface-dependent activation of blood coagulation, fibrinolysis, and inflammation. It converts prorenin to renin to activate the RAS. Teleost KLKB1-like lectin facilitates hemagglutination by binding to the pathogen-like glycoproteins, and could be involved in immune function. KLK is highly selective to release [Lys0 ]-BK from both HMW- and LMW-KNGs, which involves the hydrolysis of Met/Xaa or Leu/Xaa. Besides acting as an enzyme for KKS, KLK is also involved in proteolytic cascades for semen liquefaction through the hydrolysis of seminogelin and the desquamation of the skin by the cleavage of cellular adhesion proteins.
• Description: Plasma kallikrein possesses a unique protein structure with four apple domains and a trypsin domain, which evolved before coagulation factor XI. Tissue kallikreins are trypsinbased enzymes, and some members are highly correlated with prostate cancer. The evidence that human urine induces hypotension when injected intravenously into anesthetized dogs was first described in 1909. Two major kallikreins, plasma kallikrein (KLKB1) and tissue (glandular) kallikrein (KLK), were found in mammals, and they were transcribed by different genes. Glandular KLK was an old name and was replaced by tissue KLK in the modern nomenclature.
• Uses: Kallikrein from porcine pancreas has been used: as a matrix metalloproteinase-9 (MMP-9) zymogen activatoras a component of cell culture to test its effect on rat subventricular zone (SVZ) cells and oligodendrocyte progenitor cells (OPC) proliferation and survivalas a model enzyme to track kinetic data and visual detection limits of hydrolysis by hydrolytic enzymes in the two-phases array
• Clinical Use: Kallikreins are drug targets for the control of hypertension, inflammation, and blood coagulation diseases. They are also possible biomarkers for cancer. KLK2 and KLK3 [prostate-specific antigen (PSA)] are used as the serum biomarker for prostate cancer.